A simple meta-analytic approach for using a binary surrogate endpoint to predict the effect of intervention on true endpoint.

A surrogate endpoint is an endpoint that is obtained sooner, at lower cost, or less invasively than the true endpoint for a health outcome and is used to make conclusions about the effect of intervention on the true endpoint. In this approach, each previous trial with surrogate and true endpoints contributes an estimated predicted effect of intervention on true endpoint in the trial of interest based on the surrogate endpoint in the trial of interest. These predicted quantities are combined in a simple random-effects meta-analysis to estimate the predicted effect of intervention on true endpoint in the trial of interest. Validation involves comparing the average prediction error of the aforementioned approach with (i) the average prediction error of a standard meta-analysis using only true endpoints in the other trials and (ii) the average clinically meaningful difference in true endpoints implicit in the trials. Validation is illustrated using data from multiple randomized trials of patients with advanced colorectal cancer in which the surrogate endpoint was tumor response and the true endpoint was median survival time.

[1]  Jun Yan.  Survival Analysis: Techniques for Censored and Truncated Data , 2004 .

[2]  Jeremy M G Taylor,et al.  A Measure of the Proportion of Treatment Effect Explained by a Surrogate Marker , 2002, Biometrics.

[3]  C. Begg,et al.  On the Use of Surrogate Endpoints in Randomized Trials (with Discussion) , 2000 .

[4]  D. Rubin,et al.  Principal Stratification in Causal Inference , 2002, Biometrics.

[5]  Laurence S. Freedman,et al.  Commentary on Assessing surrogates as trial endpoints using mixed models by E. L. Korn, P. S. Albert and L. M. McShane , 2005 .

[6]  C. Begg,et al.  On the use of surrogate end points in randomized trials , 2000 .

[7]  Geert Molenberghs,et al.  Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis , 2000, The Lancet.

[8]  G. Molenberghs,et al.  The validation of surrogate endpoints in meta-analyses of randomized experiments. , 2000, Biostatistics.

[9]  Paul S Albert,et al.  Assessing surrogates as trial endpoints using mixed models , 2005, Statistics in medicine.

[10]  Maurice G. Kendall,et al.  The Advanced Theory of Statistics, Vol. 2: Inference and Relationship , 1979 .

[11]  B. Kramer,et al.  A perfect correlate does not a surrogate make , 2003, BMC medical research methodology.

[12]  M. Kendall,et al.  The advanced theory of statistics , 1945 .

[13]  B. Graubard,et al.  Statistical validation of intermediate endpoints for chronic diseases. , 1992, Statistics in medicine.

[14]  G. Izmirlian,et al.  Resolving paradoxes involving surrogate end points , 2005 .

[15]  B. Efron,et al.  A Leisurely Look at the Bootstrap, the Jackknife, and , 1983 .

[16]  M J Daniels,et al.  Meta-analysis for the evaluation of potential surrogate markers. , 1997, Statistics in medicine.

[17]  Geert Molenberghs,et al.  Validation of Surrogate Endpoints in Multiple Randomized Clinical Trials with Discrete Outcomes , 2002 .

[18]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[19]  G. Molenberghs,et al.  Criteria for the validation of surrogate endpoints in randomized experiments. , 1998, Biometrics.

[20]  Geert Molenberghs,et al.  The validation of surrogate end points by using data from randomized clinical trials: a case‐study in advanced colorectal cancer , 2004 .

[21]  R. Prentice.  Surrogate endpoints in clinical trials: definition and operational criteria. , 1989, Statistics in medicine.

[22]  R. Fisher.  The Advanced Theory of Statistics , 1943, Nature.

[23]  S. Duffy,et al.  Trial Design Based on Surrogate End Points — Application to Comparison of Different Breast Screening Frequencies , 1996 .

[24]  B. Kramer,et al.  Simple maximum likelihood estimates of efficacy in randomized trials and before-and-after studies, with implications for meta-analysis , 2005, Statistical methods in medical research.

[25]  R J Carroll,et al.  On meta-analytic assessment of surrogate outcomes. , 2000, Biostatistics.

[26]  A. Morrison.  Intermediate determinants of mortality in the evaluation of screening. , 1991, International journal of epidemiology.

[27]  Simon G. Thompson,et al.  Meta‐Analysis of Clinical Trials , 2005 .